Gilead Sciences, Inc.

NASDAQ:GILD

Drug Manufacturers - General

Healthcare
$168.98 -2.14%

-$2.69 today

Market cap
$209.59B
Beta
0.33
P/E (TTM)
16.5
EPS (TTM)
$7.42
Dividend yield
2.62%
52W Low $104.46High $157.29

Volume 4.82M

Average 6.78M

GILD Income Tax Expense

Income taxes recognized for the period, including current and deferred tax.

Gilead Sciences, Inc.NASDAQ: GILD

Income Tax Expense · Q2 FY2026 · quarter ended Jun 2026

Income tax expense dips below year-ago levels

Q2 FY2026 income tax expense of $242M fell 48.3% year over year, behind the +44.4% change in trailing-twelve-month income tax expense. Sequentially, it fell 56.7% from the prior quarter. Over 3 fiscal years it compounded at +1.0% a year.

Context

  • Income tax expense amounted to 4.4% of revenue in FY2025, up 3.6 pp from a year earlier.
  • Income tax expense increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -48.3% toward the trailing-twelve-month pace of +44.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$242M-56.7% QoQ
Last fiscal yearDec 2025
$1.29B+509.5% YoY
LTMJun 2026
$1.29B+44.4% YoY
Income Tax Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-48.3%——
1 year+509.5%——
3-year CAGR+1.0%——
5-year CAGR——
10-year CAGR——

Income Tax Expense history

USD · from the income statement

Latest · FY2025
1.29B USD
Year-over-year change
+509.5%
4-year CAGR
-11.3%

Income Tax Expense vs competitors

How GILD compares with its peers on the latest reported figures

  • Peers report in different currencies, so income tax expense is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +44.4% is the 3rd highest of 10, against a peer median of +10.8%.
  • Income tax expense amounts to 4.2% of revenue for GILD, versus a peer median of 3.6%.
GILD Competitors
Income Tax Expense for GILD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LLYEli Lilly and CompanyLTM Jun 2026$6.88B USD+125.0%+108.5%8.6%
MRKMerck & Co., Inc.LTM Jun 2026$2.78B USD+1.3%+13.5%4.2%
NVSNovartis AGLTM Jun 2026$2.78B USD+40.9%+28.6%5.0%
ABBVAbbVie Inc.LTM Sep 2026$2.47B USD+435.5%+13.1%3.7%
AZNAstraZeneca PLCLTM Sep 2026$2.25B USD+10.8%—3.6%
JNJJohnson & JohnsonLTM Sep 2026$1.64B USD-74.3%+24.6%1.7%
GILDGilead Sciences, Inc.LTM Jun 2026$1.29B USD+44.4%+1.0%4.2%
SNYSanofiLTM Jun 2026€1.2B EUR-17.1%-18.2%2.5%
GSKGSK plcLTM Jun 2026£641M GBP+0.5%+16.3%1.9%
PFEPfizer Inc.LTM Jun 2026-$164M USD+29.9%—0.3%
Peer median (excluding GILD) —+10.8%+16.3%3.6%

Competitors are the stored peer set for GILD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue27.31B27.28B27.12B28.75B29.44B
Cost of Revenue6.6B5.66B6.5B6.25B6.23B
Gross Profit20.7B21.62B20.62B22.5B23.21B
Gross Margin75.8%79.3%76.0%78.3%78.8%
Research & Development4.6B4.98B5.72B5.91B5.8B
Selling, General & Admin5.25B5.67B6.09B6.09B5.71B
Operating Expenses10.79B14.29B13.01B20.84B11.51B
Depreciation & Amortization2.05B2.1B2.69B2.77B2.76B
EBITDA11.33B8.85B10.5B4.43B13.58B
EBITDA Margin41.5%32.4%38.7%15.4%46.1%
Operating Income9.92B7.33B7.61B1.66B11.7B
Operating Margin36.3%26.9%28.0%5.8%39.7%
Interest Income0106M376M281M349M
Interest Expense1B935M944M977M1.02B
Other Income / Expenses(1.64B)(1.52B)(746M)(972M)(1.91B)
Income Before Tax8.28B5.81B6.86B690M9.8B
Pre-Tax Margin30.3%21.3%25.3%2.4%33.3%
Income Tax Expense2.08B1.25B1.25B211M1.29B
Net Income6.23B4.59B5.67B480M8.51B
Net Margin22.8%16.8%20.9%1.7%28.9%
EPS (Basic)4.963.664.540.386.84
EPS (Diluted)4.933.644.500.386.78
Weighted Avg Shares1.26B1.26B1.25B1.25B1.24B
Weighted Avg Shares (Diluted)1.26B1.26B1.26B1.26B1.26B

Gilead Sciences, Inc.

NASDAQ:GILD

Intrinsic Alpha fair value

Locked

Current Price

$168.98

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.